Colorista® capsule

Colorista® capsule
Product Description

An optimized tool for formulation development enabling compatibility studies before deciding on the final color for the commercial drug products. Available in gelatin and HPMC.​

Lonza

  • FR
  • 2015
    On CPHI since
  • 5000+
    Employees
Company types
Manufacturer/Innovator

Lonza

  • FR
  • 2015
    On CPHI since
  • 5000+
    Employees
Company types
Manufacturer/Innovator

More Products from Lonza (4)

  • Vcaps® Plus HPMC capsule

    Product Vcaps® Plus HPMC capsule

    An immediate-release HPMC capsule, without gelling agents. Vcaps® Plus capsules offer excellent dissolution profile with pH-independent performance, standard or low-moisture content, great machinability and visual quality. Also available in TiO2 free and with food colorants.
  • Zephyr(TM) DPI Delivery Solution

    Product Zephyr(TM) DPI Delivery Solution

    Custom inner surface properties, customized moisture levels and more stringent microbial limits all designed to optimize inhalant end-product performance. Available in gelatin, gelatin-PEG, Capsugel® Vcaps® and Capsugel® Vcaps® Plus.
  • DBcaps® capsule

    Product DBcaps® capsule

    DBcaps® capsules were developed with a tamper-evident design to specifically address the clinical trial challenges of testing without bias. The wider diameter of opaque DBcaps® allows containment and blinding of large-diameter or uniquely-shaped tablets or other comparator products...
  • Capsugel® Enprotect® capsule

    Product Capsugel® Enprotect® capsule

    Oral solid dosage form with first of its kind enteric manufacturing technology. 
    Discover a unique manufacturing process to build a bi-layer capsule to assist in enteric delivery. ​

Lonza resources (7)

  • News On track at CPHI Barcelona - The Track Sponsor interview: Lonza

    In our packed out content sessions at CPHI Barcelona this year we focus on some of the hottest topics coming up in the pharma industry, with each track sponsored by a leading expert in the field. 
  • Brochure Capsugel®️ Zephyr™️ Dry-Powder Inhalation Capsule Portfolio

    Dry-powder inhalation (DPI) technology offers a favorable drug development opportunity for respiratory or systemic drug delivery. Delivering a uniform dose in a portable, easy-to-use system, capsule-based DPI devices are a simple and cost-effective way to deliver inhalable medication. Capsugel® Zephyr™ is Lonza’s customizable dry-powder inhalation capsule portfolio that is optimized to provide superior performance and compatibility between the capsule/device and capsule/formulation.
  • News The Top 5 Industry Content Reads on CPHI Online

    If you’re looking for news, product information and market trends from leading pharma companies, the CPHI-Online.com Company Showcases are a great resource for buyers who want to stay up to date, browse product portfolios and find the right partner. 

    The Company Showcase profiles offer a library of free to access, downloadable content, including videos and webinars, reports, whitepapers and product brochures, from the Pharma suppliers and service providers you’d look to meet at our events.

  • Brochure Launch with Lonza™️ innovation services

    A full suite of concept-to-market services to turn ideas into breakthrough products.
  • Brochure Capsugel®️ titanium dioxide (TiO2) free white gelatin capsules

    Discover the possibilities of TiO2-free white gelatin capsules without sacrificing quality and functionality.
  • Brochure Capsugel®️ Pharmaceutical capsule portfolio

    The Capsugel®️ capsule portfolio provides a wide variety of high-quality products and technologies to help you create a customized solution to bring new innovations to market.
  • Video Making a Splash in the US Market: How PBPK Modeling is Playing a Central Role in Risk Reduction

    Rapid and efficient development of drug candidates is increasingly important for pharmaceutical companies with accelerated timelines and funding constraints. However, many early drug candidates have poor oral absorption properties making it challenging to achieve target pharmacokinetic (PK) profiles. Without upfront knowledge of absorption risks and mitigation strategies, poor absorption can significantly impact preclinical and clinical study timelines and costs. Physiologically-based pharmacokinetic (PBPK) modeling software, such as the GastroPlus® platform from Simulations Plus, simulates dynamic physiological factors impacting oral performance. When coupled with in vitro measurements, PBPK modeling is effective in early development for 1) identifying absorption risks, 2) assessing the potential for solubility enhancing formulations such as salts, cocrystals, or amorphous solid dispersions to mitigate these risks, and 3) designing and optimizing preclinical and clinical studies with respect to dose, prandial state, or gastric pH modification to maximize the likelihood of achieving desired PK profiles. In this presentation, we will demonstrate how PBPK models combined with Lonza’s custom and off-the shelf in vitro tools and solubility enhancement expertise can be used to identify and mitigate absorption risks in early drug development, reducing the need for drug product reformulation or repeated preclinical or clinical studies. Key Learning Objectives: Learn how PBPK modeling can identify potential oral absorption risks and mitigation strategies (e.g. bioavailability enhancement) for early drug candidates. Learn how PBPK modeling coupled with in vitro testing can guide early selection of drug form and formulation to achieve clinical study goals. Gain insights into how key drug and formulation factors including solubility, permeability, and dissolution rate can impact absorption risks such as poor oral bioavailability, food-drug interactions, and pH-dependent DDI effects.